secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001297184-22-000053
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY
-----------------------------------------------------------------------------

- Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).
- GAAP diluted EPS $0.30 vs $0.59 prior year; adjusted non-GAAP EPS $0.38 vs $0.46.
- Nine-month revenues $364.0M vs $316.9M; GAAP net income $57.5M vs $42.4M.
- Growth cited from epinephrine, Primatene Mist, and glucagon sales.
- No guidance issued; management optimistic about pipeline progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/0001297184-22-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/amph-20221107x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer